HEXO Corp., through its subsidiary, HEXO Operations Inc., produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names. The company serves medical and adult-use markets. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. is headquartered in Gatineau, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-406-1852
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable
HEXO (NASDAQ:HEXO) Frequently Asked Questions
What is HEXO's stock symbol?
HEXO trades on the NASDAQ under the ticker symbol "HEXO."
How were HEXO's earnings last quarter?
HEXO Corp. (NASDAQ:HEXO) issued its earnings results on Monday, December, 16th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The business had revenue of $10.95 million for the quarter, compared to the consensus estimate of $11.78 million. View HEXO's Earnings History.
When is HEXO's next earnings date?
What price target have analysts set for HEXO?
14 brokerages have issued 1-year price targets for HEXO's stock. Their forecasts range from $1.50 to $12.00. On average, they anticipate HEXO's share price to reach $4.47 in the next twelve months. This suggests a possible upside of 204.2% from the stock's current price. View Analyst Price Targets for HEXO.
What is the consensus analysts' recommendation for HEXO?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HEXO in the last year. There are currently 5 sell ratings, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for HEXO.
Has HEXO been receiving favorable news coverage?
News headlines about HEXO stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. HEXO earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for HEXO.
Who are some of HEXO's key competitors?
Some companies that are related to HEXO include Aphria (APHA), Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), OrganiGram (OGI), ORGANIGRAM-TS (OGI), Next Science (NXS), Benchmark (BMK), ICC Labs (ICC), Amryt Pharma (AMYT), Shield Therapeutics (STX), Probiotec (PBP), Green Organic Dutchman (TGOD), CannTrust (TRST) and ESSA Pharma (EPI).
What other stocks do shareholders of HEXO own?
Who are HEXO's key executives?
HEXO's management team includes the folowing people:
- Mr. Sebastien G. St-Louis, Co-Founder, Pres, CEO & Director (Age 35)
- Mr. Adam Miron, Co-founder, Chief Brand Officer & Director (Age 35)
- Mr. Ed Chaplin, CFO & Corp. Sec. (Age 49)
- Mr. James McMillan, VP of Bus. Devel. (Age 51)
- Dr. Terence Lake DVM, Vice-Pres of Corp. & Social Responsibility
Who are HEXO's major shareholders?
HEXO's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.50%), TD Asset Management Inc. (0.23%), Public Sector Pension Investment Board (0.21%), Swiss National Bank (0.16%), AdvisorShares Investments LLC (0.10%) and Bank of America Corp DE (0.10%).
Which major investors are selling HEXO stock?
HEXO stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Ladenburg Thalmann Financial Services Inc., Public Sector Pension Investment Board and TD Asset Management Inc..
Which major investors are buying HEXO stock?
HEXO stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, AdvisorShares Investments LLC, FNY Investment Advisers LLC, Jane Street Group LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Goldman Sachs Group Inc., Cambria Investment Management L.P. and Cubist Systematic Strategies LLC.
How do I buy shares of HEXO?
Shares of HEXO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is HEXO's stock price today?
One share of HEXO stock can currently be purchased for approximately $1.47.
How big of a company is HEXO?
What is HEXO's official website?
How can I contact HEXO?
The company can be reached via phone at 844-406-1852.
MarketBeat Community Rating for HEXO (NASDAQ HEXO)
MarketBeat's community ratings are surveys of what our community members think about HEXO and other stocks. Vote "Outperform" if you believe HEXO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEXO will underperform the S&P 500 over the long term. You may vote once every thirty days.
